Chandrashekaran Satish, Escalante Patricio, Kennedy Cassie C
Division of Pulmonary, Critical Care and Sleep Medicine, Lung Transplantation Program, University of Florida Gainesville, FL.
Mycobacterial and Bronchiectasis Clinic, Mayo Clinic, Rochester, MN.
J Clin Tuberc Other Mycobact Dis. 2017 Dec;9:10-18. doi: 10.1016/j.jctube.2017.08.002.
complex ( ) disease in lung transplant recipients is increasingly being recognized as an important cause of graft function decline and suboptimal outcomes. Lung transplant recipients appear to be at the highest risk of among solid organ transplant recipients, as they have more intense immunosuppression, and the organisms preferentially inhabit the lungs. is the most resistant species of rapidly growing mycobacteria and difficult to treat, causing considerable mortality and morbidity in immunocompetent and immunosuppressed patients. Herein we describe the risk factors, epidemiology, clinical features, diagnostics, and treatment strategies of in lung transplant recipients.
肺移植受者的复杂性疾病越来越被认为是移植功能下降和预后不佳的重要原因。肺移植受者似乎是实体器官移植受者中风险最高的,因为他们有更强的免疫抑制,而且这些微生物优先寄生于肺部。(此处原文缺失相关内容)是快速生长分枝杆菌中最具耐药性且难以治疗的菌种,在免疫功能正常和免疫抑制的患者中都会导致相当高的死亡率和发病率。在此,我们描述了肺移植受者中(此处原文缺失相关内容)的危险因素、流行病学、临床特征、诊断方法及治疗策略。